2.38 | 4.12%
| Price and Volume | |
|---|---|
| Recent Price | 57.80 |
| 52 Week High | 66.10 |
| 52 Week Low | 26.50 |
| Avg. Daily Vol. (Mil) | 3.72 |
| Beta (3 year) | 0.84 |
| Share Related Items | |
| Mkt Cap (Mil) | 12,199.33 |
| Shares Out (Mil) | 211.06 |
| Float (Mil) | 208.90 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 3.40 |
| Current Ratio | 4.00 |
| LT Debt/ Equity | 0.43 |
| Total Debt / Equity | 0.43 |
| Valuation Ratios | |
| Price Earnings | 42.20 |
| Price/Sales | 6.87 |
| Price/Book | 13.11 |
| Price/Cash Flow | 35.50 |
| Per Share Data | |
| Earnings | 1.37 |
| Sales | 8.41 |
| Book Value | 4.41 |
| Cash Flow | 1.63 |
| Business Summary | |
|---|---|
| Vertex Pharmaceuticals is engaged in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. | |
| General Information | |
| 130 Waverly Street
Cambridge, MA 02139 |
|
| www.vrtx.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 2000 | |
| CEO: Dr. Jeffrey M Leiden M.D | |
| Short Interest | |
| Current Month (Mil) | 7.33 |
| Previous Month (Mil) | 9.31 |
| Short Interest Ratio (Days) | 1.40 |
| Management Effectiveness | |
| Return on Equity | 31.90 |
| Return on Assets | 12.70 |
| Return on Investments | 22.30 |
| Profitability | |
| Gross Margin | 96.00 |
| EBIT Margin | 20.00 |
| Profit Margin | 16.70 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,419.86 | 1,313.32 | 2,837.36 | 16.25 |
Oil *
103.00
|
|
DOWN
160.83 |
DOWN
19.10 |
DOWN
33.63 |
DOWN
1.06 |
10 Yr
1.62%
SPDR Gold
151.91
|
|
-1.28%
|
-1.43%
|
-1.17%
|
-6.12%
|
Data delayed 20 minutes |
Connect with TheStreet